IRIS
RIMASSA, Lorenza
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.453
AS - Asia 4.715
EU - Europa 2.199
SA - Sud America 1.444
AF - Africa 291
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 12
AN - Antartide 2
Totale 19.135
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.261
SG - Singapore 2.787
BR - Brasile 1.244
CN - Cina 1.000
FI - Finlandia 449
IT - Italia 366
IE - Irlanda 334
VN - Vietnam 282
DE - Germania 268
NG - Nigeria 205
FR - Francia 172
HK - Hong Kong 162
GB - Regno Unito 135
CA - Canada 133
NL - Olanda 122
IN - India 109
SE - Svezia 85
AR - Argentina 83
TR - Turchia 63
BD - Bangladesh 61
RU - Federazione Russa 45
MX - Messico 39
JP - Giappone 38
ZA - Sudafrica 37
BE - Belgio 36
EC - Ecuador 35
IL - Israele 35
ID - Indonesia 31
CL - Cile 29
AT - Austria 28
IQ - Iraq 26
ES - Italia 25
PL - Polonia 25
UA - Ucraina 25
UZ - Uzbekistan 18
AU - Australia 16
CO - Colombia 16
SA - Arabia Saudita 16
CZ - Repubblica Ceca 14
LT - Lituania 12
PK - Pakistan 12
PY - Paraguay 12
IR - Iran 11
VE - Venezuela 11
AZ - Azerbaigian 10
MA - Marocco 10
EG - Egitto 9
PT - Portogallo 9
EU - Europa 8
KE - Kenya 8
PE - Perù 8
AE - Emirati Arabi Uniti 7
DZ - Algeria 7
KR - Corea 7
NP - Nepal 7
CH - Svizzera 6
RO - Romania 6
BY - Bielorussia 5
GR - Grecia 5
JM - Giamaica 5
JO - Giordania 5
KG - Kirghizistan 5
TN - Tunisia 5
UY - Uruguay 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
KZ - Kazakistan 3
ML - Mali 3
NI - Nicaragua 3
PH - Filippine 3
AO - Angola 2
AQ - Antartide 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
ET - Etiopia 2
GA - Gabon 2
HN - Honduras 2
HR - Croazia 2
LV - Lettonia 2
MD - Moldavia 2
NO - Norvegia 2
OM - Oman 2
PS - Palestinian Territory 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BB - Barbados 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
EE - Estonia 1
HU - Ungheria 1
IM - Isola di Man 1
KH - Cambogia 1
Totale 19.120
Salva come PNG Salva come JPEG
Città #
Dallas 1.729
Wilmington 1.287
Chandler 1.285
Singapore 835
The Dalles 597
Shanghai 557
San Mateo 477
Helsinki 449
Ann Arbor 394
Ashburn 383
Dublin 333
New York 255
Lawrence 253
Princeton 252
Boardman 243
Leawood 232
Beijing 228
Benin City 205
Hong Kong 146
Paris 140
Milan 127
Fairfield 108
Woodbridge 108
Ho Chi Minh City 107
Amsterdam 103
São Paulo 93
London 74
Los Angeles 74
Toronto 72
Santa Clara 61
Columbus 58
Phoenix 58
Hanoi 56
Seattle 51
Council Bluffs 48
San Diego 42
Kocaeli 39
Naples 36
Rio de Janeiro 36
Brussels 34
Belo Horizonte 32
Abbiategrasso 31
Brasília 31
Redwood City 31
Munich 30
Pune 30
Montreal 28
Norwalk 27
Salvador 26
Tokyo 24
Brooklyn 22
Falkenstein 22
Warsaw 21
Porto Alegre 20
Curitiba 19
Chennai 17
Tashkent 17
Campinas 16
Johannesburg 16
San Francisco 16
Atlanta 15
Guarulhos 15
Mexico City 15
Moscow 15
Redmond 15
Assago 14
Boston 14
Andover 13
Chicago 13
Guayaquil 13
Haiphong 13
Milwaukee 13
Monmouth Junction 13
Orem 13
Ribeirão Preto 13
St Louis 13
Stockholm 13
Dhaka 12
Houston 12
Da Nang 11
Hải Dương 11
Manchester 11
Quito 11
Xi'an 11
Baghdad 10
Baku 10
Brno 10
Genoa 10
Hanover 10
Asunción 9
Denver 9
Goiânia 9
Jeddah 9
Maringá 9
Ninh Bình 9
Osasco 9
Raleigh 9
São Bernardo do Campo 9
Thái Bình 9
Canoas 8
Totale 12.601
Salva come PNG Salva come JPEG
Nome #
Prognostic Factors and Survival Outcomes in Resected Biliary Tract Cancers: A Multicenter Retrospective Analysis 296
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment 207
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 163
Liver transplantation in a patient with metastatic hepatocellular carcinoma after downstaging with single-agent immunotherapy: the first case report 152
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 134
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 129
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab 119
Metastasis of hepatocellular carcinoma to the heart: A case report and review of the literature 118
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 109
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 109
5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors 102
Tivantinib for hepatocellular carcinoma 100
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer 100
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 99
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 98
Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer 97
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 96
COVID-19 and liver cancer clinical trials: not everything is lost 93
Tumor-associated macrophages and response to 5-flourouracil adjuvant therapy in stage III colorectal cancer 93
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 92
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 89
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 88
Can SBRT improve the prognosis of unresectable pancreatic cancer? Clinical results on 106 patients 88
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 88
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 88
Antiangiogenic drugs currently used for colorectal cancer: What other pathways can we target to prolong responses? 87
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 86
Biomarkers in Hepatocellular Carcinoma-Letter 85
Tumor-derived prostaglandin E2 promotes p50 NF-κB-dependent differentiation of monocytic MDSC 85
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 85
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 85
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 84
Adrenal metastases from adenocarcinoma of the esophagogastric junction: adrenalectomy and long-term survival. 84
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole 83
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 83
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 82
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 82
Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. 82
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 82
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 82
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 81
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 80
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 80
Cabozantinib for the treatment of hepatocellular carcinoma 79
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 79
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 76
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 76
High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models 76
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 76
Long-term outcomes after pancreatoduodenectomy for ampullary cancer: The influence of the histological subtypes and comparison with the other periampullary neoplasms 76
From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology 75
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer 75
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 74
Prognostic value of the immune-related transcriptome in biliary tract cancers 73
Reply to Y. Pointreau et al 73
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 73
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 73
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98 72
Clinical implications of immunohistochemical assessment of somatostatin receptors subtype 2 and 5 in the diagnostic and therapeutic management of gastro-entero-pancreatic neuroendocrine tumours 72
Characterisation of the immune-related transcriptome in resected biliary tract cancers 72
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 71
Nicotinamide phosphoribosyltransferase acts as a metabolic gate for mobilization of myeloid-derived suppressor cells 71
FOLFOX/CAPOX in stage II–III colon cancer: efficacy results of the Italian Three Or Six Colon Adjuvant trial (TOSCA) 71
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 71
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer 70
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial 70
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 70
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 69
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 69
Etiology of hepatocellular carcinoma may influence the pattern of progression under atezolizumab-bevacizumab 69
Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib 68
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 68
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 68
Medical Oncologists must get more involved in systemic treatment of Hepatocellular Carcinoma 68
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 68
F-18-FDG-PET (PET) and contrast-enhanced CT-scan (CT) in the evaluation of liver metastases from colorectal cancer after chemotherapy 68
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 68
Immunotherapy combination strategies in unresectable hepatocellular carcinoma 68
Shaping the landscape of immune oncology in hepatocellular carcinoma 67
Chemotherapy with mitomycin c and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin 67
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells 67
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 67
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 67
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. 67
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial 66
Effectiveness of precautionary chemotherapy in gastric cancer 66
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 66
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 66
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial. 66
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 66
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma 66
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 66
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up 66
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 65
Case Report of Acute Aortic Dissection during Treatment with Capecitabine for a Late Recurrence of Breast Cancer 65
Immunotherapy in hepatobiliary tumors: search for the missing pieces of the puzzle 65
Combined PD-1/VEGFR blockade: a new era of treatment for hepatocellular cancer 65
Risk of Cancer in Inflammatory Bowel Diseases: Umbrella Review and Reanalysis of Meta-analyses 64
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 64
Phase III trial comparing 3 to 6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial 64
Totale 8.408
Salva come PNG Salva come JPEG
Categoria #
all - tutte 143.487
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 143.487
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.332 0 0 0 0 0 768 355 158 455 314 33 249
2021/20221.504 61 43 20 316 28 33 70 219 136 211 270 97
2022/20233.786 563 174 342 440 302 293 35 310 675 355 257 40
2023/20242.440 161 251 455 89 76 341 161 127 36 53 278 412
2024/20253.714 121 62 29 57 75 432 284 337 580 794 424 519
2025/20265.660 1.462 1.455 1.081 1.192 339 131 0 0 0 0 0 0
Totale 19.642